Phosphorex, a contract development and manufacturing organization (CDMO) focused on drug delivery, has announced the opening of its Lipid Nanoparticle Innovation & Training Center in Hopkinton, Massachusetts. The centre aims to accelerate the success of clients’ drug development projects by
WuXi Biologics (“WuXi Bio”) has announced the launch of its WuXia RidGS platform, aimed at improving the development of therapeutic proteins, particularly monoclonal antibodies (mAbs). This innovative platform employs a glutamine synthetase (GS)-knockout CHO expression system, which leverages zinc finger
Sai Life Sciences, an Indian Contract Research, Development and Manufacturing Organization (CRDMO), announced the receipt of Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA). The reports pertain to its R&D facility (Unit II) in Hyderabad and
Medicines for Malaria Venture (MMV), in partnership with Quotient Sciences, has launched a Phase 1 clinical trial for MMV371, a new long-acting injectable designed to prevent malaria. The trial, currently underway with healthy volunteers in Nottingham, UK, will evaluate the
Pluri Inc., has announced a new collaboration with Bar-Ilan University’s research and development arm, BIRAD. Funded by the Israel Innovation Authority (IIA), the project will support the development of Placental Mucosal Associated Invariant T (MAIT) cells as a novel treatment
Chime Biologics, a global CDMO, has announced a new partnership with MedPacto, a KOSDAQ-listed South Korean company focused on developing cancer therapeutics. This strategic collaboration aims to streamline Chemistry, Manufacturing, and Controls (CMC) process development for MedPacto’s preclinical drug candidates,
This report summarises the key issues impacting prices across a range of categories in the BioPharma industry in October-November 2024. Biologics contract manufacturing The BIOSECURE Act can lead to a supply shortage of biologic products, potentially driving prices upwards. The
“Treat them as a partner, not just a supplier. It’s a mindset you need to get into.” – Federica Fraschetti, MSD Federica Fraschetti, Associate Director of External Manufacturing at MSD, brings years of experience in the pharmaceutical industry and a
AGC Biologics has named Alberto Santagostino as its new Chief Executive Officer and President, marking a shift toward becoming what it calls “Your friendly CDMO expert.” Santagostino, who steps into the role with two decades of biopharma industry experience, brings
Piramal Pharma has earmarked approximately USD 85 million in capital expenditures for the current fiscal year to support initiatives including capacity expansion, maintenance, and de-bottlenecking at its contract development and manufacturing (CDMO) sites. The company has already invested USD 30
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
